Abstract :
Readers of my original article [1] may have concluded that on the subject of Fibrosis there is a vast amount of theoretical information, [2] but for the working nephrologists there is only the knowledge that treating patients with a combination of ACE inhibitors and ARBs could lessen fibrosis, or alternatively there is the Et-1 antagonist bosentan, which is not entirely free of side-effects.
